This single-arm, phase 2 nonrandomized clinical trial assesses the efficacy and safety of combined pembrolizumab, bevacizumab, and oral metronomic cyclophosphamide in women with recurrent platinum-sensitive, platinum-resistant, or refractory epithelial ovarian, fallopian tube, or primary peritoneal cancer.
This cohort study investigates the long-term reproductive outcomes in women who did or did not undergo fertility preservation at the time of breast cancer diagnosis.
This cohort study assesses the concordance of 3 models to stratify risk for progression to multiple myeloma in an independent cohort of patients with smoldering multiple myeloma.
This systematic review reports the outcomes and evidence in randomized clinical trials of nonpharmacological treatment options for alleviating breathlessness and their implications for clinical guidelines and practice in advanced cancer.
This Viewpoint argues that specialty generics can cost more for patients than brand-name drugs, and proposes strategies to protect patients by addressing the market dysfunction caused by rebates.
This nonrandomized clinical trial evaluates molecular recurrence and patient-reported outcomes after tyrosine kinase inhibitor discontinuation in US patients with chronic myeloid leukemia.
This nonrandomized controlled trial reports the oncological outcomes of the deintensification (from 50 Gy to 36 Gy) of a preoperative radiotherapy regimen for adults with myxoid liposarcoma.
This case series examines clinical characteristics, experiences, and outcomes of transgender patients with cancer.
This survey study examines the attitudes of a large group of cancer survivors toward trial participation during the coronavirus disease 2019 outbreak.
A 73-year-old man with metastatic colorectal cancer presents with crusted lesions and purulent drainage on the scalp, with associated pruritus and pain. What is your diagnosis?
This essay describes how an act of kindness can restore one’s hope.
This phase 3 randomized clinical trial assesses the efficacy of a clinician-driven treatment choice vs a circulating tumor cell count–driven choice for first-line treatment among women with hormone receptor–positive, ERBB2-negative metastatic breast cancer.
This randomized clinical trial evaluates clinical outcomes in patients with ERBB2-negative metastatic breast cancer treated with indoximod plus a taxane.
This case series study examines the prevalence of clonal hematopoiesis and its potential interference in prostate cancer cell-free DNA testing.
This cohort study examines the implementation of a microbiologic screening pilot program in Al Zahra Hospital in the United Arab Emirates for identifying presymptomatic COVID-19 in patients with cancer.
This Viewpoint discusses approvals by the US Food and Drug Administration for first- and second-line chemotherapy drugs—plus the combined use of some agents—used to treat hepatocellular carcinoma.
Create a personal account or sign in to: